Full Text View
Tabular View
No Study Results Posted
Related Studies
Intravitreal Sirolimus as Therapeutic Approach to Uveitis (SAVE-2)
The recruitment status of this study is unknown because the information has not been verified recently.
Verified January 2011 by Johns Hopkins University.
Recruitment status was  Not yet recruiting
Study NCT01280669   Information provided by Johns Hopkins University

First Received on January 20, 2011.   No Changes Posted
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Uveitis
Intermediate Uveitis
Posterior Uveitis
Panuveitis
Additional conditions recognized in this trial
Chorioretinitis
Pars Planitis
Uveitis, Intermediate
Uveitis, Posterior
More general conditions related to this trial
Choroid Diseases
Choroiditis
Eye Diseases
Retinal Diseases
Retinitis
Uveal Diseases
Interventions listed in this trial
Intravitreal injection 440mcg
Additional drug interventions recognized in this trial
Everolimus
Sirolimus
More general drug interventions related to this trial
Anti-Bacterial Agents
Anti-Infective Agents
Antibiotics, Antineoplastic
Antifungal Agents
Antineoplastic Agents
Immunologic Factors
Immunosuppressive Agents
Pharmacologic Actions
Physiological Effects of Drugs
Therapeutic Uses
Sponsors listed in this trial
Johns Hopkins University
Santen Inc.


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services